Search - tctmd.com

Displaying 1 - 20 of 69

Sort: Relevancy | Date

The Biggest News of 2022: TCTMD’s Top 10

News Opinion Editor's Corner

The Biggest News of 2022: TCTMD’s Top 10

December 30, 2022

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

News Daily News

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

Michael O'Riordan

December 14, 2022

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

Sequencing HF Meds? Most Doctors Stick to Old Habits, Survey Says

News Daily News

Sequencing HF Meds? Most Doctors Stick to Old Habits, Survey Says

December 08, 2022

Think Before You Shake: UK Biobank Data Link Added Salt to Long-term CVD Risks

News Daily News

Think Before You Shake: UK Biobank Data Link Added Salt to Long-term CVD Risks

November 30, 2022

Sodium Restriction No Help, No Harm in HF, Meta-analysis Confirms

News Daily News

Sodium Restriction No Help, No Harm in HF, Meta-analysis Confirms

November 23, 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

November 10, 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends

News Conference News AHA 2022

STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends

November 07, 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

News Conference News AHA 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

November 05, 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

News Conference News AHA 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

Yael L. Maxwell

November 01, 2022

From Cannabis to Opioids, Meth, and Cocaine: Drugs Are Linked to More AF

News Daily News

From Cannabis to Opioids, Meth, and Cocaine: Drugs Are Linked to More AF

October 27, 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

News Conference News HFSA 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

October 07, 2022

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

October 05, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

News Conference News HFSA 2022

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

October 04, 2022

TCT 340: Intermittent Occlusion of the Superior Vena Cava Improves Urine Sodium Excretion in Patients with Acutely Decompensated Heart Failure

Presentation TCT 2022

TCT 340: Intermittent Occlusion of the Superior Vena Cava Improves Urine Sodium Excretion in Patients with Acutely Decompensated Heart Failure

Presenter: Rayan Yousefzai

September 18, 2022

Dedicated Catheter for Acute PE Shows Promise in IDE Trial

News Conference News TCT 2022

Dedicated Catheter for Acute PE Shows Promise in IDE Trial

September 17, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.